诺和诺德向美国食品药品监督管理局（FDA）重新提交了阿维克利（AWIQLI）的上市申请，该药物有望成为首款用于治疗成人 2 型糖尿病的每周一次基础胰岛素疗法。
Source Link诺和诺德向美国食品药品监督管理局（FDA）重新提交了阿维克利（AWIQLI）的上市申请，该药物有望成为首款用于治疗成人 2 型糖尿病的每周一次基础胰岛素疗法。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.